{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:21:49Z","timestamp":1781126509655,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.radonc.2024.110639","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:27:43Z","timestamp":1732022863000},"page":"110639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-5691","authenticated-orcid":false,"given":"Marcin","family":"Kubeczko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9096-2788","authenticated-orcid":false,"given":"Dorota","family":"Gabry\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-331X","authenticated-orcid":false,"given":"Justyna","family":"Rembak-Szynkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8275-0422","authenticated-orcid":false,"given":"Donata","family":"Gr\u00e4upner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-7067","authenticated-orcid":false,"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.radonc.2024.110639_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2944","article-title":"Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: A nationwide cohort study","volume":"13","author":"Sihto","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"20","key":"10.1016\/j.radonc.2024.110639_b0010","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.radonc.2024.110639_b0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Harstell","year":"2005","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110639_b0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejmp.2019.07.023","article-title":"Re-irradiation of vertebral bodies","volume":"64","author":"Gabry{\\acute{s}}","year":"2019","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2024.110639_b0025","doi-asserted-by":"crossref","unstructured":"Maciejewski BA, Gabry{\\acute{s}} D, Napieralska A. Re-irradiation: the \u201csome like it hot \u2013 others not\u201d dilemma [Internet]. Vol. 74, Nowotwory. Via Medica; 2024 [cited 2024 Oct 18]. p. 123\u201333. Available from: www.nowotwory.edu.pl.","DOI":"10.5603\/njo.98856"},{"key":"10.1016\/j.radonc.2024.110639_b0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.radonc.2013.06.013","article-title":"Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up","volume":"108","author":"Vignard","year":"2013","journal-title":"Radiothe Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110639_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01693-w","article-title":"CDK4\/6 inhibitors: A novel strategy for tumor radiosensitization","volume":"39","author":"Yang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.radonc.2024.110639_b0040","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-3575","article-title":"Abemaciclib, a Selective CDK4\/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer in vitro and in vivo","volume":"24","author":"Naz","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.radonc.2024.110639_b0045","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1158\/1078-0432.CCR-20-2269","article-title":"Short-term CDK4\/6 inhibition radiosensitizes estrogen receptor-positive breast cancers","volume":"26","author":"Pesch","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110639_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2019.02.049","article-title":"P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy","volume":"1","author":"Fern\u00e1ndez-Aroca","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2024.110639_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ijrobp.2019.06.2531","article-title":"Inhibition of CDK4\/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas","volume":"105","author":"G\u00f6ttgens","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110639_b0060","article-title":"Radiosensitizing effects of CDK4\/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-\u03baB-signaling pathway","volume":"1","author":"Yang","year":"2024","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2024.110639_b0065","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-20-3871","article-title":"Radiotherapy delivered before CDK4\/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer","volume":"27","author":"Petroni","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110639_b0070","doi-asserted-by":"crossref","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. 2019 [cited 2022 Dec 25];5(1):1\u20138. Available from: https:\/\/www.nature.com\/articles\/s41523-018-0097-z.","DOI":"10.1038\/s41523-018-0097-z"},{"issue":"1","key":"10.1016\/j.radonc.2024.110639_b0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110639_b0080","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.radonc.2024.110639_b0085","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.radonc.2024.110639_b0090","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol [Internet]."},{"issue":"9","key":"10.1016\/j.radonc.2024.110639_b0095","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.radonc.2024.110639_b0100","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.radonc.2024.110639_b0105","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med [Internet]."},{"issue":"6","key":"10.1016\/j.radonc.2024.110639_b0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radonc.2024.110639_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100939","article-title":"Enhanced toxicity with CDK 4\/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature","volume":"14","author":"David","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.radonc.2024.110639_b0120","doi-asserted-by":"crossref","unstructured":"Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. 2019 May 1 [cited 2021 May 20];24(3):276\u201380. Available from: www.sciencedirect.com.","DOI":"10.1016\/j.rpor.2019.03.001"},{"key":"10.1016\/j.radonc.2024.110639_b0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2018.09.020","article-title":"Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment","volume":"1","author":"Kawamoto","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110639_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102586","article-title":"Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis","volume":"119","author":"Becherini","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2024.110639_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109839","article-title":"Safety and feasibility of CDK4\/6 inhibitors treatment combined with radiotherapy in patients with HR-positive\/HER2-negative breast cancer. A systematic review and meta-analysis","volume":"187","author":"Kubeczko","year":"2023","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2024.110639_b0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 11)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.radonc.2024.110639_b0145","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2024.110639_b0150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.radonc.2024.110639_b0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.radonc.2024.110639_b0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.55409","article-title":"Stereotactic body and conventional radiotherapy for painful bone metastases: A systematic review and meta-analysis","volume":"7","author":"Bindels","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2024.110639_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102586","article-title":"Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis","volume":"119","author":"Becherini","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"10.1016\/j.radonc.2024.110639_b0170","doi-asserted-by":"crossref","first-page":"25691","DOI":"10.18632\/oncotarget.14823","article-title":"The role of radiation therapy in bone metastases management","volume":"8","author":"De Felice","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2024.110639_b0175","doi-asserted-by":"crossref","unstructured":"McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC clinical trials group symptom control trial SC.23. JAMA Oncol [Internet]. 2017 Jul 1 [cited 2024 Oct 10];3(7):953\u20139. Available from: https:\/\/jamanetwork-com.ezp-prod1.hul.harvard.edu\/journals\/jamaoncology\/fullarticle\/2601221.","DOI":"10.1001\/jamaoncol.2016.6770"},{"key":"10.1016\/j.radonc.2024.110639_b0180","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breastcancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024043019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024043019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:30:56Z","timestamp":1734586256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024043019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0167814024043019"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110639","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110639"}}